Fig. 1: Transcriptional control of ADAMTS2 in SCZ patients at onset and after 3-month antipsychotic treatment. | Translational Psychiatry

Fig. 1: Transcriptional control of ADAMTS2 in SCZ patients at onset and after 3-month antipsychotic treatment.

From: Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics

Fig. 1

Relative mRNA expression level of ADAMTS2 gene in PBMCs from peripheral blood samples of an independent cohort of SCZ patients: healthy controls (basal; grey bar), untreated FEP patients (basal drug-naïve; black bar) and 3-month treated patients (striped bar). FEP: first episode of psychosis. All patients were treated with risperidone or aripiprazole drugs and showed clinical response to treatment (Cohort: patients N = 30 and controls N = 10). Data are mean ± SEM; unpaired Wilcoxon’s signed-rank test: ***p < 0.001 compares patients at baseline vs. healthy controls; paired Wilcoxon’s signed-rank test: ###p < 0.001 compares patients at baseline vs. those after 3-month AP treatment.

Back to article page